세계의 염증성 장질환 치료 시장 예측(-2030년) : 유형별, 약물군별, 투여 경로별, 유통 채널별, 지역별 분석

According to Stratistics MRC, the Global Inflammatory Bowel Disease Treatment Market is accounted for $21.47 billion in 2023 and is expected to reach $31.44 billion by 2030 growing at a CAGR of 5.6% during the forecast period. The term "inflammatory bowel disease" (IBD) is used to describe ulcerative colitis and Crohn's disease, two conditions in which the GI tract is chronically inflamed. The digestive system becomes damaged over time by inflammation. The goal of treating irritable bowel syndrome is to reduce the inflammation that is the source of your signs and symptoms. In the best-case scenario, this might lead to symptom relief, a long-term remission, and lowered complications risks. For the treatment of IBD, drugs or surgery are usually employed.

According to ClinicalTrials.gov., there are currently 965 clinical trials being undertaken in the United States alone out of the 2,784 clinical trials (including medication development, observational studies, and others) connected to IBD.

Market Dynamics:

Driver:

Increasing prevalence of disease is presenting a large patient pool undergoing treatment

Many factors, including genetic predisposition, environmental triggers, and immune system disturbances, are responsible for the rising prevalence of ulcerative colitis and Crohn's disease. The majority of individuals who have ulcerative colitis or Crohn's disease have a family history of the condition. By educating the public about these diseases' symptoms, diagnoses, and treatments, a number of government agencies are raising public awareness of these illnesses. Therefore, it is projected that growing consumer awareness of various treatment alternatives and rising disease diagnosis rates in developing nations will boost market expansion.

Restraint:

High cost

In underdeveloped nations, there is a lack of knowledge regarding inflammatory bowel disease, which lowers the number of individuals receiving treatment. Additionally, it is anticipated that high treatment costs, including those associated with drugs and other expenses, may restrict the use of an inflammatory bowel disease treatment among patients. Additionally, biologics are being used more frequently to treat ulcerative colitis and Crohn's disease, but the market expansion is being constrained by the high costs of biologic treatment.

Opportunity:

Strong portfolio of pipeline molecules to increase product launches

Some of the reasons driving the growth of the inflammatory bowel disease treatment market include the rising prevalence of Crohn's disease and ulcerative colitis, as well as increased awareness of the condition on a global scale. As a result, a number of important industry firms are concentrating on R&D and looking into new prospective candidates for the treatment of IBD.

Threat:

Limited pipeline of new drugs and technical challenges

The number of new medications being developed to treat IBD is rather small, and most of them focus on similar mechanisms of action. The pharmaceutical industry may find it harder to differentiate its medicines as a result, which may put pressure on prices. A number of laws, including those governing clinical trials, labeling, and safety monitoring, pertain to the IBD market. For pharmaceutical companies, complying with these rules can be time- and money-consuming.

COVID-19 Impact:

The market for treating inflammatory bowel disease expanded more slowly during the predicted period as a result of COVID-19's effects. The closure of diagnostic facilities, travel restrictions, and lockdowns in numerous nations worldwide are a few of the causes contributing to the disease's delayed rate of treatment. The revenue generated in 2020 was significantly lower than it was in 2019.

The crohn's disease segment is expected to be the largest during the forecast period

The Crohn's disease segment is expected to hold the largest share during the forecast period. The rising incidence of Crohn's disease and the number of people undergoing treatment for it internationally are both credited with driving the expansion of this market. For instance, according to the Deutsches Arztblatt, there are 100 to 200 cases of Crohn's disease per 100,000 people in Germany.

The injectables segment is expected to have the highest CAGR during the forecast period

Due to rising product approvals for biologics as well as rising biologic usage for the treatment of ulcerative colitis and Crohn's disease, the injectables sector is anticipated to have the highest CAGR over the projection period. For instance, AbbVie Inc. announced in February 2021 that the FDA had approved HUMIRA for the treatment of moderate to severe active ulcerative colitis in juvenile patients. Through subcutaneous injections, HUMIRA is administered. Thus, the expansion of the injectables sector is supported by the rising demand for biologics for the treatment of IBD.

Region with largest share:

North America dominated the global market for the treatment of inflammatory bowel disease as a result of the existence of numerous powerful market players and the numerous strategic initiatives they carried out there. Additionally, the region's improved reimbursement practices, high treatment rates, and rising prescription of innovative treatments are aiding regional expansion. The region's expansion is also predicted to be fueled by continuous efforts to discover innovative therapies and supportive government initiatives.

Region with highest CAGR:

Over the forecast period, Asia-Pacific is expected to experience the highest growth. Some of the key reasons driving market expansion in the upcoming years include an aging population, a high chance of developing inflammatory diseases, an increase in the prevalence of inflammatory bowel diseases, and better healthcare policies in the area. Additionally, increased investments by top players in the region and the increasing acceptance of biosimilars and biologics are anticipated to fuel market expansion in the near future.

Key players in the market:

Some of the key players in Inflammatory Bowel Disease Treatment market include: Allergan plc., Janssen Biotech, Celltrion Inc., Pfizer Inc, Merck & co., inc, Bristol-myers squibb company, Bausch health companies inc, Takeda Pharmaceutical Company Limited, Novartis AG, UCB S.A., Amgen Inc, Johnson & Johnson Services, Inc, Biogen and AbbVie Inc.

Key Developments:

In October 2021, Bristol-Myers Squibb Company announced the approval of Zeposia (ozanimod) by the Committee for Medicinal Products for Human Use (CHMP) for the treatment of adults with moderately to severely active Ulcerative Colitis (UC).

In February 2021, the European Commission (EC) granted marketing authorization to CELLTRION INC.'s Yuflyma biosimilar used to treat adult and pediatric Crohn's disease and ulcerative colitis.

Types Covered:

• Ulcerative Colitis
• Crohn's Disease

Drug Class Covered:

• JAK inhibitors
• Anti-integrin
• IL inhibitors
• TNF inhibitors
• Corticosteroids
• Aminosalicylates
• Other Drug Class

Route of Administrations Covered:

• Injectable
• Oral

Distribution Channels Covered:

• Online Pharmacy
• Retail Pharmacy
• Hospital Pharmacy

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Inflammatory Bowel Disease Treatment Market, By Type

• 5.1 Introduction
• 5.2 Ulcerative Colitis
• 5.3 Crohn's Disease

6 Global Inflammatory Bowel Disease Treatment Market, By Drug Class

• 6.1 Introduction
• 6.2 JAK inhibitors
• 6.3 Anti-integrin
• 6.4 IL inhibitors
• 6.5 TNF inhibitors
• 6.6 Corticosteroids
• 6.7 Aminosalicylates
• 6.8 Other Drug Class

7 Global Inflammatory Bowel Disease Treatment Market, By Route of Administration

• 7.1 Introduction
• 7.2 Injectable
• 7.3 Oral

8 Global Inflammatory Bowel Disease Treatment Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Online Pharmacy
• 8.3 Retail Pharmacy
• 8.4 Hospital Pharmacy

9 Global Inflammatory Bowel Disease Treatment Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Allergan plc.
• 11.2 Janssen Biotech
• 11.3 Celltrion Inc.
• 11.4 Pfizer Inc
• 11.5 Merck & co., inc
• 11.6 Bristol-myers squibb company
• 11.7 Bausch health companies inc
• 11.8 Takeda Pharmaceutical Company Limited
• 11.9 Novartis AG
• 11.10 UCB S.A.
• 11.11 Amgen Inc
• 11.12 Johnson & Johnson Services, Inc
• 11.13 Biogen
• 11.14 AbbVie Inc.,